BACKGROUND: To address whether umbilical cord blood concentrations of sex steroid hormones and the insulin-like growth factor (IGF) axis differ between African-American and White male neonates. METHODS: In 2004 and 2005, venous cord blood samples were collected from 75 African-American and 38 White male full-term uncomplicated births along with birth weight, placental weight, mother's age and parity, and time of birth. Testosterone, androstanediol glucuronide, estradiol, and sex hormone binding globulin (SHBG) were measured by immunoassay, and IGF-I, IGF-2, and IGF binding protein (BP)-3 by ELISA. Crude and multivariable-adjusted geometric mean concentrations were computed. RESULTS: Androstanediol glucuronide, estradiol, and SHBG concentrations did not differ by race; however, the molar ratio of testosterone to SHBG was higher in African-American than White male babies after adjustment (P = 0.01). Both before and after adjustment, Whites had higher concentrations of IGF-I (adjusted; White, African-American, 93.1, 71.9 ng/mL), IGF-2 (537.3-474.8 ng/mL), and IGFBP-3 (1,673-1,482 ng/mL) than African-Americans (P < 0.05), although the molar ratio of IGF-I plus IGF-2 to IGFBP-3 did not differ by race. CONCLUSION: The higher cord blood testosterone to SHBG ratio in African-American compared with White male babies after taking into account maternal and birth factors is compatible with the hypothesis that differences in androgen levels in utero contribute to their higher prostate cancer risk, although we would have expected crude differences as well. Lower cord blood IGF-I and IGF-2 levels in African-American compared with White male babies are not consistent with the hypothesis that differences in growth factor levels contribute to their higher prostate cancer risk.
BACKGROUND: To address whether umbilical cord blood concentrations of sex steroid hormones and the insulin-like growth factor (IGF) axis differ between African-American and White male neonates. METHODS: In 2004 and 2005, venous cord blood samples were collected from 75 African-American and 38 White male full-term uncomplicated births along with birth weight, placental weight, mother's age and parity, and time of birth. Testosterone, androstanediol glucuronide, estradiol, and sex hormone binding globulin (SHBG) were measured by immunoassay, and IGF-I, IGF-2, and IGF binding protein (BP)-3 by ELISA. Crude and multivariable-adjusted geometric mean concentrations were computed. RESULTS:Androstanediol glucuronide, estradiol, and SHBG concentrations did not differ by race; however, the molar ratio of testosterone to SHBG was higher in African-American than White male babies after adjustment (P = 0.01). Both before and after adjustment, Whites had higher concentrations of IGF-I (adjusted; White, African-American, 93.1, 71.9 ng/mL), IGF-2 (537.3-474.8 ng/mL), and IGFBP-3 (1,673-1,482 ng/mL) than African-Americans (P < 0.05), although the molar ratio of IGF-I plus IGF-2 to IGFBP-3 did not differ by race. CONCLUSION: The higher cord blood testosterone to SHBG ratio in African-American compared with White male babies after taking into account maternal and birth factors is compatible with the hypothesis that differences in androgen levels in utero contribute to their higher prostate cancer risk, although we would have expected crude differences as well. Lower cord blood IGF-I and IGF-2 levels in African-American compared with White male babies are not consistent with the hypothesis that differences in growth factor levels contribute to their higher prostate cancer risk.
Authors: E A Platz; M N Pollak; E B Rimm; N Majeed; Y Tao; W C Willett; E Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-12 Impact factor: 4.254
Authors: O Ukkola; J Gagnon; T Rankinen; P A Thompson; Y Hong; A S Leon; D C Rao; J S Skinner; J H Wilmore; C Bouchard Journal: Eur J Endocrinol Date: 2001-07 Impact factor: 6.664
Authors: A Ekbom; J Wuu; H O Adami; C M Lu; P Lagiou; D Trichopoulos; C Hsieh Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-02 Impact factor: 4.254
Authors: Colin P Hawkes; Deirdre M Murray; Louise C Kenny; Mairead Kiely; Jonathan O'B Hourihane; Alan D Irvine; Zengru Wu; Yair Argon; Richard E Reitz; Michael J McPhaul; Adda Grimberg Journal: Horm Res Paediatr Date: 2018-01-18 Impact factor: 2.852
Authors: Jessica M Faupel-Badger; Yuping Wang; S Ananth Karumanchi; Frank Stanczyk; Michael Pollak; Thomas McElrath; Robert N Hoover; Rebecca Troisi Journal: Cancer Causes Control Date: 2011-09-24 Impact factor: 2.506
Authors: Wan-yee Tang; Lisa M Morey; Yuk Yin Cheung; Lynn Birch; Gail S Prins; Shuk-mei Ho Journal: Endocrinology Date: 2011-11-22 Impact factor: 4.736
Authors: Kathirvel Gopalakrishnan; Jay S Mishra; Vijayakumar Chinnathambi; Kathleen L Vincent; Igor Patrikeev; Massoud Motamedi; George R Saade; Gary D Hankins; Kunju Sathishkumar Journal: Hypertension Date: 2016-01-18 Impact factor: 10.190
Authors: Kari A Weber; Christopher M Heaphy; Corinne E Joshu; Jiayun Lu; Sabine Rohrmann; Jessica L Bienstock; Tanya Agurs-Collins; Alan K Meeker; Elizabeth A Platz Journal: Cancer Causes Control Date: 2018-07-06 Impact factor: 2.506